Azome Therapeutics Inc
Azome Therapeutics is an early-stage drug discovery company focused on developing selective antagonists of the NLRP3 inflammasome, a critical inflammatory pathway involved in various severe inflammatory diseases. Their lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks upstream signals in the NLRP3 inflammatory cascade, aiming to treat diseases such as acute lung injury, ARDS, BPD, sepsis, and pneumonia.
Industries
Nr. of Employees
small (1-50)
Products
RHAMM-derived inflammasome antagonist (lead preclinical candidate)
A RHAMM-derived antagonist designed to disrupt RHAMM–hyaluronan interactions and prevent aberrant NLRP3 inflammasome activation; demonstrated in vitro potency/selectivity and efficacy in multiple preclinical models of lung and systemic inflammation.
RHAMM-derived inflammasome antagonist (lead preclinical candidate)
A RHAMM-derived antagonist designed to disrupt RHAMM–hyaluronan interactions and prevent aberrant NLRP3 inflammasome activation; demonstrated in vitro potency/selectivity and efficacy in multiple preclinical models of lung and systemic inflammation.
Services
Collaborative preclinical development programs with translational research centers to generate data in support of Investigational New Drug submissions.
Collaborative preclinical development programs with translational research centers to generate data in support of Investigational New Drug submissions.
Expertise Areas
- NLRP3 inflammasome therapeutics
- RHAMM-targeted drug discovery
- Peptide therapeutics and stapled peptides
- Preclinical pharmacology and in vivo efficacy modeling
Key Technologies
- RHAMM antagonists (HA-binding site mimicry)
- NLRP3 inflammasome inhibition assays
- Stapled peptide chemistry and cyclic peptide methodology
- In vivo models of lung injury and bronchopulmonary dysplasia (neonatal hyperoxia)
News & Updates
Collaboration focuses on studies of AZM-152 to enable submission of an Investigational New Drug (IND) application for the prevention of BPD in preterm infants.
Azome Therapeutics, an early-stage drug development company, presented data supporting its Receptor for Hyaluronan-Mediated Motility (RHAMM) antagonist technology at the 6th Annual Inflammasome Therapeutics Summit held September 10-12 in Boston, MA.
Azome Therapeutics announced that it will present at the upcoming BioNJ Biopartnering Conference on May 14, 2024, highlighting its RHAMM antagonist platform and lead candidate AZM-152.
Azome announced a CRADA with NCATS to investigate AZM-152 for the prevention of BPD in preterm infants, including preclinical development studies.
Collaboration focuses on studies of AZM-152 to enable submission of an Investigational New Drug (IND) application for the prevention of BPD in preterm infants.
Azome Therapeutics, an early-stage drug development company, presented data supporting its Receptor for Hyaluronan-Mediated Motility (RHAMM) antagonist technology at the 6th Annual Inflammasome Therapeutics Summit held September 10-12 in Boston, MA.
Azome Therapeutics announced that it will present at the upcoming BioNJ Biopartnering Conference on May 14, 2024, highlighting its RHAMM antagonist platform and lead candidate AZM-152.
Azome announced a CRADA with NCATS to investigate AZM-152 for the prevention of BPD in preterm infants, including preclinical development studies.